Evaluation of the angiogenesis inhibitor KR-31831 in SKOV-3 tumor-bearing mice using 64Cu-DOTA-VEGF121 and microPET

Nuclear Medicine and Biology

Volumn 39, Issue 6, 2012, Pages 840-846

  Lee, Iljung ^a   Yoon, Kwang Yup ^a   Kang, Choong Mo ^a   Lin, Xin ^b   Chen, Xiaoyuan ^b   Kim, Jung Young ^c   Kim, Sung Min ^d   Ryu, Eun Kyoung ^d   Choe, Yearn Seong ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

^c Korea Institute of Radiation and Medical Science   (South Korea)

^d Korea Basic Science Institute (KBSI)   (South Korea)

Author keywords

64Cu DOTA VEGF121; Angiogenesis; KR 31831; MicroPET; VEGFR2

Indexed keywords

6 AMINO 4 [N (4 CHLOROPHENYL) N (1H IMIDAZOL 2YLMETHYL)AMINO] 3 HYDROXYL 2 METHYL 2 DIMETHOXYMETHYL 3,4 DIHYDRO 2H 1 BENZOPYRAN; ANGIOGENESIS INHIBITOR; CD31 ANTIGEN; KR 31831; TRACER; UNCLASSIFIED DRUG; VASCULOTROPIN 121 TETRAXETAN CU 64; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MOLECULAR IMAGING; MOUSE; NONHUMAN; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION;

ANGIOGENESIS INHIBITORS; ANIMALS; BENZOPYRANS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; IMIDAZOLES; MICE; ORGANOMETALLIC COMPOUNDS; OVARIAN NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84864009464     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.01.007     Document Type: Article

References (26)

1. Panns A.M.J. The use of radiotracers in drug discovery and development. Drug Discov Today 2003, 8:734.
2. 11C]-N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in rats and humans prior to phase I clinical trials. Cancer Res 1997, 57:2172-2180.
3. Osman S., Rowlinson-Busz G., Luthra S.K., Aboagye E.O., Brown G.D., Brady F., et al. Comparative biodistribution and metabolism of carbon-11-labeled N-[2-(dimethylamino)ethyl]acridine-4-carboxamide and DNA-intercalating analogues. Cancer Res 2001, 61:2935-2944.
4. Saleem A., Harte R., Matthews J., Osman S., Brady F., Luthra S., et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001, 19:1421-1429.
5. Farde L., Andrée B., Ginovart N., Halldin C., Thorberg S. PET determination of robalzotan [NAD-299] induced 5-HT[1A] receptor occupancy in the monkey brain. Neuropsychopharmacol 2000, 22:422-429.
6. Yi E.Y., Park S.Y., Song H.S., Son M.J., Yi K.Y., Yoo S.E., et al. KR-31831, a new synthetic anti-ischemic agent, inhibits in vivo and in vitro angiogenesis. Exp Mol Med 2006, 38:502-508.
7. Park S.Y., Seo E.H., Song H.S., Jung S.Y., Lee Y.K., Yi K.Y., et al. KR-31831, benzopyran derivative, inhibits VEGF-induced angiogenesis of HUVECs through suppressing KDR expression. Int J Oncol 2008, 32:1311-1315.
8. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004, 25:581-611.
9. Roskoski R. Vascular endothelial growth factor (VEGF) signaling in tumor progression. Crit Rev Oncol Hematol 2007, 62:179-213.
10. Takahashi Y., Kitadai Y., Bucana C.D., Cleary K.R., Ellis L.M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995, 55:3964-3968.
11. Underiner T.L., Ruggeri B., Gingrich D.E. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004, 11:731-745.
12. Dougher-Vermazen M., Hulmes J.D., Böhlen P., Terman B.I. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem Biophys Res Commun 1994, 205:728-738.
13. Seetharam L., Gotoh N., Maru Y., Neufeld G., Yamaguchi S., Shibuya M. A unique signal transduction from FLT tyrosine kinase, a receptor for vascular endothelial growth factor VEGF. Oncogene 1995, 10:135-147.
14. Cohen T., Gitay-Goren H., Sharon R., Shibuya M., Halaban R., Levi B.Z., et al. VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J Biol Chem 1995, 270:11322-11326.
15. Ma S.H., Le H.B., Jia B.H., Wang Z.X., Xiao Z.W., Cheng X.L., et al. Peripheral pulmonary nodules: relationship between multi-slice spiral CT perfusion imaging and tumor angiogenesis and VEGF expression. BMC Cancer 2008, 8:186.
16. Zhang H.T., Scott P.A., Morbidelli L., Peak S., Moore J., Turley H., et al. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 2000, 83:63-68.
17. Guo P., Xu L., Pan S., Brekken R.A., Yang S.T., Whitaker G.B. Vascular endothelial growth factor isoforms display distinct activities in promoting tumor angiogenesis at different anatomic sites. Cancer Res 2001, 6123:8569-8577.
18. Cai W., Chen K., Mohamedali K.A., Cao Q., Gambhir S.S., Rosenblum M.G., et al. PET of vascular endothelial growth factor receptor expression. J Nucl Med 2006, 47:2048-2056.
19. 64Cu-labeled vascular endothelial growth factor-121 positron emission tomography. Circulation 2008, 117:915-922.
20. Cai W., Guzman R., Hsu A.R., Wang H., Chen K., Sun G., et al. Positron emission tomography imaging of poststroke angiogenesis. Stroke 2009, 40:270-277.
21. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989, 24:148-154.
22. 18F-FDG-microPET or external caliper. BMC Med Imaging 2008, 8:16.
23. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., McLaren J., Barker P.J., Wright K.A., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995, 87:506-516.
24. Wang F., Barfield E., Dutta S., Pua T., Fishman D.A. VEGFR-2 silencing by small interference RNA (siRNA) suppresses LPA-induced epithelial ovarian cancer (EOC) invasion. Gynecol Oncol 2009, 115:414-423.
25. Sher I., Adham S.A., Petrik J., Coomber B.L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009, 124:553-561.
26. Wang H., Cai W., Chen K., Li Z.B., Kashefi A., He L., et al. A new PET tracer specific for vascular endothelial growth factor receptor 2. Eur J Nucl Med Mol Imaging 2007, 34:2001-2010.